US 10428050
Substituted reverse pyrimidine Bmi-1 inhibitors
granted A61KA61K31/506A61K45/06
Quick answer
US patent 10428050 (Substituted reverse pyrimidine Bmi-1 inhibitors) held by PTC THERAPEUTICS, INC. expires Mon Sep 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- PTC THERAPEUTICS, INC.
- Grant date
- Tue Oct 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Sep 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 8
- CPC classes
- A61K, A61K31/506, A61K45/06, A61P, A61P35/00